<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771340</url>
  </required_header>
  <id_info>
    <org_study_id>IT-003</org_study_id>
    <nct_id>NCT02771340</nct_id>
  </id_info>
  <brief_title>Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma</brief_title>
  <official_title>A Phase 1, Open-label, Multicenter Study Evaluating the Safety and Tolerability, Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Who Are Planned to Undergo Enucleation or Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iconic Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iconic Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, biological activity,
      pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal
      doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo
      enucleation or brachytherapy of the affected eye.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>30 days (plus or minus 5 days) after surgical procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma levels of ICON-1</measure>
    <time_frame>1 day after last dose of ICON-1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity (BCVA)</measure>
    <time_frame>On or 1 day prior to surgical procedure day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Uveal Melanoma</condition>
  <condition>Choroid Neoplasm</condition>
  <arm_group>
    <arm_group_label>ICON-1 0.3 mg Singe Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single intravitreal dose of ICON-1 0.3 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICON-1 0.3 mg Repeat Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICON-1 0.6 mg Repeat Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ICON-1</intervention_name>
    <description>Intravitreal injection of ICON-1</description>
    <arm_group_label>ICON-1 0.3 mg Singe Dose</arm_group_label>
    <arm_group_label>ICON-1 0.3 mg Repeat Dosing</arm_group_label>
    <arm_group_label>ICON-1 0.6 mg Repeat Dosing</arm_group_label>
    <other_name>human Immuno-conjugate 1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females of any race at least 18 years of age

          -  Clinical diagnosis of primary uveal melanoma involving the posterior uveal tract in
             the study eye

          -  Planned enucleation or brachytherapy of the study eye due to uveal melanoma

        Exclusion Criteria:

          -  Uveal melanoma in the study eye originating in the anterior uveal tract (iris)

          -  Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia)

          -  Woman who is pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriela Burian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Iconic Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cureom.org</url>
    <description>CURE OM (Community United for Research and Education of Ocular Melanoma)</description>
  </link>
  <link>
    <url>http://www.ocularmelanoma.org</url>
    <description>Ocular Melanoma Foundation (OMF)</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
    <mesh_term>Choroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

